Akorn Inc. has voluntarily recalled 15,170 ampules of Fentanyl Citrate Injection, USP (100 mcg/2 mL). This recall was issued because laboratory testing found that the total impurity level in the medication was 4.1%, which is higher than the approved safety limit of 3.0%. About 15,170 units are affected by this issue, which was discovered during routine testing of retained samples. Consumers should contact their doctor or pharmacist regarding any products from the affected lot, as the degradation of the medication may impact its performance.
The presence of impurities above the specified limit means the drug has degraded more than allowed, which could potentially result in reduced effectiveness or unexpected side effects for the patient.
Healthcare provider consultation and pharmacy refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.